Many mechanisms could explain the lack of efficacy of checkpoint inhibitors, such as loss of major histocompatibility complex-I expression, a low level of tumor neo-antigens, or poor CD8 infiltration.[1–3]. This evidence concerns the gene CD8A and neoplasm.